Eduardo de la Rosa Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eduardo de la Rosa Fernández has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jesús del Pozo Losada
Servicio de Dermatología del Complexo Hospitalario Universitario de A Coruña, A Coruña, España
2 shared publications - María Elena Gatica Ortega
Department of Dermatology Complejo Hospitalario Universitario de Toledo Toledo Spain
2 shared publications - R. Fernández de Misa Cabrera
Servicio de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España
2 shared publications - Sara Becerril Andrés
Servicio de Dermatología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
2 shared publications Sara Dorta‐Alom
Dermatology Department Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife Spain
2 shared publications- Ana Maria Giménez Arnau
Department of Dermatology Hospital del Mar Research Institute Barcelona Spain
1 shared publication
Latest Publications
- 31 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Severe Local Skin Reaction to Topical 5‐Fluorouracil
- 31 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Severe Local Skin Reaction to Topical 5‐Fluorouracil
- Open Access
- 9 October 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , T1057-T1065
[Translated article] The Reality of Migration by Patera Boats: Morbidity and Dermatological Injuries
- 9 October 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , T1057-T1065
Open Access[Translated article] The Reality of Migration by Patera Boats: Morbidity and Dermatological Injuries
- Open Access
- 5 September 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Angio‐histiocitoma de células multinucleadas: entidade independente ou variante de dermatofibroma? Rosetas e linhas brancas brilhantes como novos achados dermatoscópicos
- 5 September 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Open AccessAngio‐histiocitoma de células multinucleadas: entidade independente ou variante de dermatofibroma? Rosetas e linhas brancas brilhantes como novos achados dermatoscópicos
- Open Access
- 18 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501183
Multinucleated cell angiohistiocytoma: independent entity or variant of dermatofibroma? Rosettes and shiny white lines as new dermoscopic findings
- 18 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501183
Open AccessMultinucleated cell angiohistiocytoma: independent entity or variant of dermatofibroma? Rosettes and shiny white lines as new dermoscopic findings
- Open Access
- 3 July 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , 1057-1065
La realidad de la migración en patera: descripción de la morbilidad asociada y caracterización de las lesiones cutáneas
- 3 July 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , 1057-1065
Open AccessLa realidad de la migración en patera: descripción de la morbilidad asociada y caracterización de las lesiones cutáneas
- 20 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (5) , 379-386
An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.Objective: To evaluate a case series of ACD to PE in Spain.Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch‐tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.
- 20 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (5) , 379-386
An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.Objective: To evaluate a case series of ACD to PE in Spain.Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch‐tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.
- 1 May 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (2) , 174-176
Severe allergic contact dermatitis to bisabolol and phytonadione epoxide found in a moisturizing and strengthening facial cream
- 1 May 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (2) , 174-176
Severe allergic contact dermatitis to bisabolol and phytonadione epoxide found in a moisturizing and strengthening facial cream
- 7 May 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (9) , e1104-e1106
Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management
- 7 May 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (9) , e1104-e1106
Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management